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Abstract 
Despite advances in anti-emetic therapy, chemotherapy-induced nausea and vomiting (CINV) 
still poses a significant burden to patients undergoing chemotherapy. Nausea, in particular,  is 
still highly prevalent in this population. Ginger has been traditionally used as a folk remedy 
for gastrointestinal complaints and has been suggested as a viable adjuvant treatment for 
nausea and vomiting in the cancer context. Substantial research has revealed ginger to 
possess properties that could exert multiple beneficial effects on chemotherapy patients who 
experience nausea and vomiting. Bioactive compounds within the rhizome of ginger, 
particularly the gingerol and shogaol class of compounds, interact with several pathways that 
are directly implicated in CINV in addition to pathways that could play secondary roles by 
exacerbating symptoms. These properties include 5-HT3, substance P and acetylcholine 
receptor antagonism; anti-inflammatory properties; and modulation of cellular redox 
signalling, vasopressin release, gastrointestinal motility, and gastric emptying rate. This 
review outlines these proposed mechanisms by discussing the results of clinical, in vitro and 
animal studies both within the chemotherapy context and in other relevant fields. The 
evidence presented in this review indicates that ginger possesses multiple properties that 
could be beneficial in reducing chemotherapy-induced nausea and vomiting. 
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Introduction 
Chemotherapy-induced nausea and vomiting (CINV) is a significant burden for patients 
undergoing anticancer chemotherapy. Nausea and vomiting are rated as two of the most 
distressing symptoms by chemotherapy patients and have been shown to  significantly and 
adversely affect quality of life and physical function during treatment.(Carelle et al., 2002; 
Sun et al., 2005) Ratings of quality of life can be reduced by as much as 20% in patients who 
experience CINV compared to symptom-free patients.(Lindley et al., 1992) Additionally, 
CINV is associated with malnutrition and further physical complications such as acid-base 
imbalance and electrolyte disturbances.(Davidson et al., 2012; Lindley and Hirsch, 1992; 
Osoba, 2005) All of these issues affect the patients’ ability to adhere to, or complete 
chemotherapy, resulting in a potential concomitant impact on survival outcomes.  
Despite significant improvement in the control of CINV through the use of modern anti-
emetics such as 5-HT3 antagonists, corticosteroids and NK1 antagonists, nausea and vomiting 
still affects up to 60% and 37% of patients undergoing chemotherapy, respectively.(Bloechl-
Daum et al., 2006)   
Ginger has traditionally been used for centuries as a treatment for gastrointestinal complaints 
and more recently has been investigated for its use in treating motion sickness, post-operative 
nausea and vomiting, and morning sickness in clinical studies.(Ernst and Pittler, 2000) A 
recent systematic review of randomised-controlled trials that investigated the effect of ginger 
as an adjuvant treatment for CINV found that the literature was equivocal with significant 
limitations.(Marx et al., 2013)  
An array of compounds are bioactive within the rhizome of ginger, such as shogaols, 
gingerols, zingerone, and paradols.(Baliga et al., 2011) These compounds are typically 
categorised into two classes: volatile oils and non-volatile pungent compounds. Both of these 
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classes of compounds are contained within the oleoresin, the collective term for the oil and 
resin fraction of the rhizome. While the concentration of these compounds varies greatly 
depending on the country of origin, storage, and preparation of the ginger product, the 
gingerol and shogaol compounds are likely to be the primary components responsible for 
ginger’s pharmacological effects. These compounds are believed to interact with multiple 
areas implicated in the development of CINV. Specific properties of these compounds that 
may be relevant to CINV include 5-HT3, substance P and acetylcholine receptor antagonism; 
anti-inflammatory properties; and modulation of cellular redox signalling, vasopressin 
release, gastrointestinal motility, and gastric emptying rate.(Abdel-Aziz et al., 2006; Prakash 
and Srinivasan, 2010; Wu et al., 2008; Zick et al., 2011) Whereas recent reviews have 
focused upon the clinical efficacy of ginger, this paper will focus on the potential 
mechanisms by which ginger could exert anti-CINV effects.  
Physiology of CINV 
The physiology of CINV is a complex neural interaction involving central and peripheral 
stimuli and reactions. While multiple pathways are involved in CINV, this discussion will 
focus on the primary pathway of CINV (i.e 5-HT3 and NK1 antagonism) and pathways that 
could potentially be modulated by ginger (Figure 1). The site of the initial trigger of CINV is 
thought to be within the gastrointestinal tract. Chemotherapy agents interact with 
enterochromaffin cells, possibly via oxidative stress, resulting in a release of the 
neurotransmitters serotonin and substance P.(Torii et al., 1994a) The released 
neurotransmitters then interact with receptors located upon the vagus nerve, which 
subsequently transmits afferent signals to the chemotherapy receptor zone within the brain 
via the nucleus tractus solitarius. It is thought that modern 5-HT3 antagonist medications (e.g. 
ondansetron) interact with the 5-HT3 receptors involved in this process, which then mitigates 
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the degree of afferent signalling. Another neurotransmitter, substance P, has also been 
implicated in the generation of CINV by binding to NK1 receptors located centrally within 
the brain. Stimuli transmitted using these two neuropeptides, as well as stimuli from other 
regions of the brain, are processed by the chemoreceptor trigger zone and vomiting centre, 
which then coordinates the relevant musculature to induce a nausea and/or vomiting 
response.(Rudd, 2005)  
While not directly involved in the generation of CINV, other secondary pathways could 
exacerbate the experience of nausea and vomiting in this setting. These include the 
modulation of gastric emptying, increased inflammation, and vestibular and vasopressin-
related mechanisms.(Cawley and Benson, 2005; Rudd, 2005; Sharma and Gupta, 1998)  
Chemotherapy agents such as cisplatin and methotrexate are known to delay gastric 
emptying, potentially resulting in gastrointestinal distress due to antral distension.(Sharma 
and Gupta, 1998) Research related to chemotherapy-induced mucositis has demonstrated that 
pro-inflammatory signalling pathways, particularly nuclear factor kappa-B (NF-κB), are 
increased within the gastrointestinal mucosa as a result of chemotherapy-induced cell injury. 
It has been suggested that this increase in gut inflammation might contribute to the 
development of CINV, particularly during the delayed phase (≥24 hours after 
chemotherapy)(Rudd, 2005) which is supported by the increase in inflammatory cytokines 
largely occurring between 2-10 days post-chemotherapy.(Cawley and Benson, 2005)    
The vestibular system, which is located within the inner ear, is involved in providing a sense 
of balance. While the vestibular system might not be a primary pathway in the development 
of CINV, vestibular disturbances are implicated in the exacerbation of CINV. In support of 
this, the vestibular system is involved in the development of motion sickness, which is a 
known risk factor for CINV.(Leventhal et al., 1988) Furthermore, scopolamine, a 
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pharmacological treatment for motion sickness, has demonstrated efficacy in reducing CINV 
when used in conjunction with other anti-emetic medications, but not when used as a stand-
alone treatment.(Longo et al., 1982; Meyer et al., 1987) This suggests that the vestibular 
system plays a secondary role in the development of CINV.   
Lastly, it has been suggested that vasopressin (also known as antidiuretic hormone) 
contributes to the sensation of nausea in chemotherapy patients. Studies have demonstrated 
that vasopressin is significantly increased in patients experiencing CINV(Fisher et al., 1982; 
Rudd, 2005)  and that the  administration of supraphysiological doses of endogenous 
vasopressin is sufficient to induce nausea in healthy human participants.(Caras et al., 1997)  
However, other studies do not support this hypothesis. For example, when vasopressin was 
administered at physiological doses, nausea was not experienced.(Kim et al., 1997) This has 
lead researchers to suggest that vasopressin may play a modulatory role in the generation of 
CINV instead.(Rudd, 2005)  
Proposed mechanisms of action 
Interaction with neurotransmitters and vagal afferent signalling 
Results from in vitro and animal studies demonstrate that ginger is likely to exert 5-HT3 
antagonistic effects. Yamahara et al.(Yamahara et al., 1989) were the first to demonstrate that 
whole ginger, as well as 6-, 8- and 10-gingerols, could inhibit 5-HT3-induced contractions in 
an isolated guinea pig ileum. Huang et al.(Huang et al., 1991) demonstrated inhibition of 5-
HT3-induced contractions using the ginger compound, galanolactone. However, these two 
studies have significant limitations.(Abdel-Aziz et al., 2006) Both studies used serotonin to 
induce contractions, not an agonist that is selective for 5-HT3 receptors. This allows for the 
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possibility that ginger inhibited the action of serotonin on another receptor, making the exact 
mechanism of action unclear.(Abdel-Aziz et al., 2006) 
 Additionally, Huang et al.(Huang et al., 1991) studied galanolactone, a compound only 
found in Japanese ginger and which therefore cannot be extrapolated to other types of 
ginger.(Abdel-Aziz et al., 2006; Ravindran and Babu, 2004)  
To address these limitations, Abdel-Aziz et al.(Abdel-Aziz et al., 2006) investigated the 
effect of four major compounds found in ginger, namely 6-, 8- and 10-gingerol and 6-
shogaol, on 5-HT3-mediated contractions in an isolated rat ileum using a selective 5-HT3 
agonist. The results indicated that these compounds significantly inhibited contractions 
induced by this agonist; however, all four compounds failed to displace the 5-HT3 receptor 
antagonist, [
3
H]GR65630, from binding to the 5-HT3 receptor. It was therefore concluded 
that the mechanism of action of ginger, at least in relation to 5-HT3 pathways, is most likely 
due to indirect modulation of 5-HT3 signalling through the binding of an alternative, 
unidentified site.(Abdel-Aziz et al., 2006) Additionally, the authors reported that these 
compounds weakly inhibited acetyl-choline and substance P-induced contractions, suggesting 
additional mechanisms for the anti-CINV effects of ginger. 
Modulation of gastrointestinal motility and gastric emptying 
Metoclopramide has been used for decades as an anti-emetic in chemotherapy, partly due to 
its prokinetic effect on the gastrointestinal system.(Schapira et al., 1990) Research, 
particularly from in vitro studies, suggest that ginger is also likely to affect gastrointestinal 
motility and gastric emptying.(Hashimoto et al., 2002; Hu et al., 2011; Wu et al., 2008) While 
gastrointestinal dysmotility may not play a direct role in the generation of CINV, it may play 
a secondary role by contributing to other gastrointestinal symptoms such as bloating, early 
satiety, and abdominal pain.   
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Multiple animal and in vitro studies indicate that whole ginger as well as specific compounds 
within ginger affect gastric emptying rates and gastrointestinal contractions. For example, 
Hashimoto et al.(Hashimoto et al., 2002) demonstrated that 6-shogaol improved muscle 
contractions and charcoal-induced transit time in porcine small intestines. Similarly, acetone 
ginger extract as well as the ginger components, 6-shogoal, 6-. 8-, and 10-gingerol, all 
enhanced the transport of a charcoal meal in mice.(Yamahara et al., 1990) Furthermore, both 
an ethanolic and acetone extract of ginger as well as ginger juice all reversed cisplatin-
induced delayed gastric emptying in rats.(Sharma and Gupta, 1998)  In contrast, the ginger 
compounds zingerone and zingerol as well as whole ginger were reported to inhibit colonic 
motility in rats.(Iwami et al., 2011a; Iwami et al., 2011b) These diverse results indicate that 
ginger’s effects could be a result of the particular concentration of different bioactive 
compounds, or the synergy between them.  
The effect of ginger on gastrointestinal motility in human participants has been investigated 
in multiple studies; however, the degree to which the results of these studies can be 
extrapolated to the CINV setting is limited as no study has been conducted with patients 
undergoing chemotherapy to date. This is likely due to CINV-related anti-emetic research 
focusing on other pathways (i.e 5-HT3-mediated CINV) and the burden that such a study may 
place on patients undergoing chemotherapy; however, relief from symptoms related to 
gastrointestinal dysmotility could prove to be effective as a secondary measure of CINV 
management and therefore, future research in the CINV setting is recommended.  
To date, six studies have examined the effect of ginger on gastrointestinal motility in varied 
patient populations, including healthy participants and participants with dyspepsia or 
admitted to an intensive care unit.(Hu et al., 2011; Micklefield et al., 1999; Phillips et al., 
1993; Shariatpanahi et al., 2010; Stewart et al., 1991; Wu et al., 2008) However, the 
significant differences in methodology employed in these studies makes comparison difficult. 
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Differences included the dosage of ginger, the composition of the test meal used, and the 
instrument used to measure gastric emptying and motility. Scintography is the recommended 
method to evaluate gastric empting.(Abell et al., 2008) However, due to the use of radioactive 
materials in this technique and the risk attendant on this, alternative methods are 
preferred.(Wu et al., 2008) While the use of alternative methods might reduce the equipment 
costs and expertise required, they are not as sensitive and could introduce confounders.  For 
example, in one study of intensive care patients, when gastric emptying was measured by the 
amount of feeding tolerated over a 48 hour period by participants, ginger improved gastric 
motility.(Shariatpanahi et al., 2010) However, in an another study that evaluated gastric 
emptying by a similarly indirect method (the measurement of paracetamol absorption), 
Phillips et al.(Phillips et al., 1993) found 1g of ginger had no effect on gastric emptying. The 
indirect measures used in these two studies provided a lower level of precision. The results 
could also be influenced by other factors, such as the nutrient density of the test meal, its 
fluid and macronutrient content and its total volume. All of these factors can influence the 
rate of gastric emptying; hence, a nutrient-dense test meal is critical when measuring rates of 
gastric emptying.(Wu et al., 2008) Because no test meal was used in this study, significant 
delays in gastric emptying would not be expected.  A similarly non-nutrient-dense test meal 
was used in a study of the effect of 500mg of ginger on gastric emptying rates.(Stewart et al., 
1991)  The failure of this study to demonstrate efficacy in relation to ginger could be a result 
of the 75kcal solution used as the test meal, which may have been insufficient to induce an 
effect.(Stewart et al., 1991) 
Wu et al.(Wu et al., 2008) and Hu et al.(Hu et al., 2011) addressed many of these limitations 
by using a dose of 1.2g of ginger and a test meal with a relatively high caloric content 
(118kcal in both studies). The two studies found that ginger was effective at reducing gastric 
emptying rates in both healthy and dyspeptic participants. A smaller dose of ginger (200mg) 
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has also demonstrated effectiveness in increasing gastrointestinal motility in healthy 
volunteers.(Micklefield et al., 1999)  
In summary, animal studies as well as most human studies conducted to date (66%) suggest 
ginger modulates the rate of gastric emptying and gastrointestinal motility. However, no 
studies so far have investigated the effect in participants undergoing chemotherapy and 
therefore, the applicability of these results to the chemotherapy setting is currently unclear.  
Anti-oxidant properties 
Oxidative stress, defined as an over production of reactive oxygen species, has been reported 
to be linked to the etiology of the emetic reflex. One of the initial steps in the generation of 
CINV is believed to be the generation of free radicals by chemotherapy agents within the 
gastrointestinal tract which in turn leads to the release of neurotransmitters from 
enterochromaffin cells.(Torii et al., 1994b)  This notion has led to investigations of the 
antioxidant activity of ginger. In vitro experiments have demonstrated the antioxidant kinetic 
behaviour of isolated compounds extracted from the dried rhizomes of ginger, subjected to a 
1,1-diphenyl-2-picrylhydrazyl radical scavenging reaction.(Masuda et al., 2004) 
However, there are no clear human clinical trials or animal experiments that demonstrate that 
ginger extracts might modulate CINV via an antioxidant effect. Given that the oxidative 
stress/antioxidant theory of cellular metabolism has been challenged,(Linnane et al., 2007) an 
alternative plausible biochemical explanation for ginger’s effect on CINV is the rebalancing 
of the disrupted cellular oxido-reductase mechanism that often accompanies chemotherapy 
treatments.(Linnane et al., 2007) 
Anti-inflammatory properties 
During chemotherapy, cell injury caused within the gastrointestinal tract (GIT) results in the 
release of multiple inflammatory factors including cyclooxygenase-2 (COX-2), interleukin-6 
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(IL-6), and nuclear factor kappa-B (NF-kB). The end result of this pathway is continued 
tissue damage and potentially mucositis along the length of the GIT.(Sultani et al., 2012) It 
has been suggested that inflammation and cell injury may be particularly involved in the 
delayed phase of CINV.(Hesketh, 2005)  
In vitro research has found that multiple ginger compounds are able to elicit an anti-
inflammatory effect through a number of pathways including the inhibition of NF-kB, COX 
enzymes, and 5-lipoxogenase.(van Breemen et al., 2011) Ginger compounds have also 
demonstrated an anti-inflammatory effect in murine and rat models, with these effects 
replicated in human clinical trials.(Ojewole, 2006; Zick et al., 2011)  For example, 28 days of 
ginger supplementation (2g) in humans modulated eicosanoid synthesis in the colonic 
mucosa by lowering prostaglandin-2 levels in healthy participants(Zick et al., 2011) and 
COX-1 in participants who were at risk of colon cancer.(Jiang et al., 2012) Additionally, a 
review that included 8 clinical trials in this field concluded that while there is a paucity of 
well-designed trials, there is tentative evidence that ginger possesses anti-inflammatory 
properties in the treatment of pain related to osteoarthritis, dysmenorrhea, and exercise.(Terry 
et al., 2011)  
In summary, while these studies did not directly measure the effect of ginger on inflammation 
during chemotherapy, the current literature indicates that ginger is likely to modulate 
inflammation in the gut and this could contribute to ginger’s anti-CINV effects.   
Vestibular interactions 
Acetylcholine and histamine are two neurotransmitters involved in the development of 
motion sickness. In vitro studies demonstrate that ginger compounds have antagonistic 
properties to both muscarinic and histaminergic receptors and therefore, represent a potential 
pathway by which ginger may interact with the vestibular system.(Abdel-Aziz et al., 2006) 
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Clinical trials have largely confirmed this effect in clinical or experimentally-induced motion 
sickness. Eight trials were identified in our review, of which five reported ginger to be either 
superior to placebo or equal to standard anti-motion sickness medications. (Grontved et al., 
1988; Grontved and Hentzer, 1986; Holtmann et al., 1989; Lien et al., 2003; Mowrey and 
Clayson, 1982; Schmid et al., 1994; Stewart et al., 1991; Wood et al., 1988) Therefore, it is 
likely that ginger is able to interact with signalling involved in the vestibular system and 
could potentially modulate CINV symptoms. 
Modulation of vasopressin 
Ginger is known to reduce plasma vasopressin in adults exposed to experimentally-induced 
motion sickness; however, when endogenous vasopressin was injected, ginger was ineffective 
in preventing nausea.(Lien et al., 2003) This suggests that ginger exerts an indirect action on 
vasopressin release. However, to date there is only one study measuring ginger’s effect on 
vasopressin. Future studies are required to confirm these effects in the chemotherapy setting. 
Furthermore, the exact role of vasopressin in CINV needs to be elucidated before this can be 
considered a clinically-relevant mechanism.  
Conclusion 
CINV is a significant burden experienced by many oncology patients. While the control of 
overt vomiting has advanced, it is still prevalent and nausea remains stubbornly problematic 
for numerous chemotherapy patients. Ginger contains a wide array of bioactive compounds 
that can potentially act on multiple pathways involved in the physiology of CINV (Figure 1). 
These pathways include the modulation of relevant neuropeptides, vasopressin release and 
gastrointestinal motility as well as redox and anti-inflammatory signalling. The clinical 
evidence for its use in the treatment in CINV is currently equivocal;(Marx et al., 2013) 
however, the data presented in this paper demonstrate an array of viable mechanisms of 
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action and provide a sound foundation for continued research in this area. Of primary 
importance is the need for future trials to investigate these beneficial properties in the 
chemotherapy setting.  
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Figure 1. Proposed anti-CINV mechanisms of action of ginger.  
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